Dr Reddy's CEO Erez Israeli expects a healthy performance in the second half of FY2026-27 once the company resolves the semaglutide issue. Israeli believes the generics market for semaglutide in will be ultra-competitive, with more than 20 companies trying to gain market share. (Source: Bloomberg)
Dr Reddy's CEO Erez Israeli expects a healthy performance in the second half of FY2026-27 once the company resolves the semaglutide issue. Israeli believes the generics market for semaglutide in will be ultra-competitive, with more than 20 companies trying to gain market share. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/62a563ce7aef923608053b8248e01e63d7a99eb5" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Dr Reddy's CEO On Clogged Semaglutide Pipeline"></iframe>
